Liraglutide

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

(2015) Caroline M. Apovian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

AACE Comprehensive Diabetes Management Algorithm 2013

(2015) Alan Garber et al.   Endocrine Practice

Prevalence of Childhood and Adult Obesity in the United States, 2011-2012

(2014) Cynthia L. Ogden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes

(2013) S. H. Kim et al.   DIABETES CARE

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin

(2013) Mojca Jensterle Sever et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

(2013) M E J Lean et al.   INTERNATIONAL JOURNAL OF OBESITY

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study

(2013) T A Wadden et al.   INTERNATIONAL JOURNAL OF OBESITY

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

(2013) Michael D. Jensen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

(2013) Caroline M. Apovian et al.   Obesity

An overview of the pharmacokinetics, efficacy and safety of liraglutide

(2012) Bruce Bode   DIABETES RESEARCH AND CLINICAL PRACTICE

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

(2011) A Astrup et al.   INTERNATIONAL JOURNAL OF OBESITY

A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial

(2011) Meredith C. Fidler et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)

(2011) David B. Allison et al.   Obesity

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus

(2010) Eduard Montanya et al.   CLINICAL THERAPEUTICS

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2010) Frank L Greenway et al.   LANCET

Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management

(2010) Steven R. Smith et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus

(2009) Joshua J Neumiller et al.   ANNALS OF PHARMACOTHERAPY

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

(2009) Lisbeth V. Jacobsen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Annual Medical Spending Attributable To Obesity: Payer-And Service-Specific Estimates

(2009) Eric A. Finkelstein et al.   HEALTH AFFAIRS

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Comment on: Lachin et al. (2007) The Hemoglobin Glycation Index Is Not an Independent Predictor of the Risk of Microvascular Complications in the Diabetes Control and Complications Trial: Diabetes 56:1913-1921, 2007

(2008) S. Chalew et al.   DIABETES

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET